Skip to content
Orbsen Therapeutics Logo Orbsen Therapeutics Logo
  • Home
  • Technologies
  • Pipeline
  • About
  • Leadership
  • Partnerships
  • Media
  • Contact
Homeorbsen2023-01-31T23:17:03+00:00
  • Orbsen Therapeutics
    “Redefining cell therapy”

In the News

orbsen2023-01-31T23:16:28+00:00

Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease

orbsen2023-01-31T21:24:45+00:00

Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says

orbsen2020-04-10T17:40:14+00:00

Orbsen Therapeutics Launches Clinical Trial to Address Leading Cause of Death Among COVID-19 Patients

orbsen2019-07-01T18:03:10+00:00

Minister opens new Business Innovation Centre for life sciences start-ups

orbsen2019-04-03T21:28:42+00:00

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland

orbsen2019-04-09T20:49:47+00:00

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations

Product Pipeline

We are working on the development of an extensive range of therapies based on our proprietary technologies. The targets for these therapies include:

  • Diabetic Foot Ulcers
  • Acute Respiratory Distress Syndrome – ARDS
  • Diabetic Kidney Disease – DKD
  • Primary Sclerosing Cholangitis – PSC
Copyright 2021 | Orbsen Therapeutics | All Rights Reserved | Cookie Policy
facebook